A Rift Over Carl Linnaeus Shows We Shouldn’t Idolize Scientists
By Brian Lovett,
Undark
| 08. 06. 2020
The traditions we carry into the future, including who we choose to honor, should be able to withstand modern scrutiny.
WE ARE LIVING through a period of cultural upheaval. Around the world, statues of iconic men who held racist beliefs and committed racial injustices are being ripped from their pedestals. The dull thud of metal bodies hitting concrete rings fresh in our ears, and many of us are still grappling with what these reverberations mean.
Statues of racists are monuments to the dregs of our society. Yet over time, their pedestals have crept so high that, for some people, it has become unthinkable that any scandal could justify their removal. Today, these memorialized men look down on us from high places that they do not deserve; the scandal is that society has for so long respected the inertia of their corrupting influence.
One such figure is the 18th century Swedish botanist Carl Linnaeus. He devised binomial nomenclature, the ubiquitous system now used to scientifically classify organisms by genus and species. He then used his nomenclature to classify humans by “variety,” ascribing inherently positive traits to lighter-skinned Europeans and negative traits to darker-skinned Africans and Asians, thereby laying a pseudoscientific foundation for...
Related Articles
Since the “CRISPR babies” scandal in 2018, no additional genetically modified babies are known to have been born. Now several techno-enthusiastic billionaires are setting up privately funded companies to genetically edit human embryos, with the explicit intention of creating genetically modified children.
Heritable genome editing remains prohibited by policies in the overwhelming majority of countries that have any relevant policy, and by a binding European treaty. Support for keeping it legally off limits is widespread, including among scientists...
By Angus Liu, Fierce Pharma | 06.16.2025
A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile.
Sarepta and its ex-U.S. partner Roche reported the death early Sunday. Like the first case, disclosed...
By Sophie Alexander and Ike Swetlitz, Bloomberg | 06.25.2025
A California-startup focused on genetically editing human embryos — a step toward creating so-called designer babies — is raising money as many of Silicon Valley’s ultra-rich turn their attention to one of the most controversial technologies in medicine.
Bootstrap Bio...
